Bulk Drug Substances Lists
Bulk drug substances lists are the FDA registers that decide which raw active ingredients a compounding pharmacy or outsourcing facility may use when no monograph or approved drug covers them.
A compounder cannot lawfully use any active ingredient it can buy. Under section 503A a bulk substance qualifies only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list; under section 503B the only route is FDA's list of substances for which there is a clinical need. Both lists are built by nomination, reviewed with advisory committee input, and revised over time.
While a nomination is pending, FDA has run an interim policy that sorts substances into categories: broadly, those it may consider further and does not currently intend to act against, and those it has flagged as presenting significant safety risks, on grounds such as immunogenicity, unresolved impurities or the absence of any meaningful human characterisation. Several peptides circulating in wellness practice have been moved into the adverse category on exactly those grounds. Because assignments change as evidence is submitted, the current FDA lists rather than a secondary summary decide what may be used today.
This is the single most useful check on a peptide's real regulatory footing. A molecule with no monograph, not a component of any approved drug, and absent from both bulks lists cannot lawfully be compounded for a patient in the United States at all, whatever a clinic's website implies. It reframes the question from whether something can be bought to whether any lawful route exists by which it could reach a patient.
The dodge to recognise is relabelling. The same substance ineligible for compounding is often sold as a research chemical, asserted to be a dietary ingredient, or routed through export and reimport. None of that alters its position on the lists; it alters only who is left carrying the liability, which is usually the prescriber and the patient.